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656Background: Aminoglycoside treatment has been associated with nephrotoxic effects. However, the effect of
perioperative aminoglycoside treatment on the risk of acute kidney injury requiring dialysis among patients un-
dergoing cardiac surgery remains uncertain.
Methods: We performed a register study based on prospectively collected data from population-based health
care databases of 3625 consecutive patients undergoing cardiac surgery at the Aarhus University Hospital,
Skejby, Denmark. Patients requiring preoperative dialysis were excluded, leaving a total of 3587 patients
(99% of original patient cohort), of whom 89 received perioperative aminoglycosides.
Results: The cumulative risk of in-hospital dialysis-dependent acute kidney injury was 3.2% (n ¼ 115). Peri-
operative use of aminoglycosides was associated with an increased risk of postoperative dialysis (adjusted odds
ratio [OR], 4.41; 95% confidence interval [CI], 1.83–10.59). Other predictors included reoperation because of
bleeding (adjusted OR, 2.80; 95%CI, 1.63–4.80), use of inotropic support during anesthesia (adjusted OR, 2.10;
95% confidence interval, 1.49–2.95), and cardiopulmonary bypass lasting longer than 120 minutes (adjusted
OR, 1.95; 95% CI, 1.19–3.20) along with EuroSCORE variables. Postoperative dialysis was associated with
higher 30-day mortality (10.9% vs 2.5%, P<.0001, c2 test), but use of aminoglycosides was not independently
associated with mortality.
Conclusions: Perioperative use of aminoglycosides in adults undergoing cardiac surgery was associated with
increased risk of postoperative dialysis. (J Thorac Cardiovasc Surg 2011;142:656-61)The role of aminoglycoside treatment in relation to cardiac
surgery remains controversial. Aminoglycosides are still
widely used as standard prophylactic antibiotics in cardiac
surgery. However, the efficacy of aminoglycosides as an ad-
ditional prophylactic is not well established.1
It has been suggested to replace aminoglycosides with
other antibiotics.2 A major issue is the possible nephrotoxic
effect of aminoglycosides, which are currently considered
one of the most frequent causes of iatrogenic renal injury.3
Previous studies have suggested that perioperative use of
aminoglycosides in cardiac surgery is associated with
changes in elimination kinetics of aminoglycosides resulting
in an increase in serum creatinine levels.4,5 However, the
association between aminoglycoside treatment and
postoperative dialysis in patients requiring cardiopulmonary
bypass (CPB) remains uncertain.
The aim of this study was to examine the association
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The Journal of Thoracic and Cardiovascular Surgrisk of postoperative acute kidney injury and subsequent
dialysis in adults undergoing cardiac surgery.
MATERIALS AND METHODS
The studywas approved by the DanishData ProtectionAgency.We con-
ducted this cohort study by using population-based health care databases,
with the civil registry number assigned to each Danish citizen at birth
used to link data across the databases.6
Study Population
Computerized data from theWestern Denmark Heart Registry (WDHR)
were used to identify all consecutive patients undergoing cardiac surgery at
Aarhus University Hospital, Skejby, from January 1, 2003, to December
31, 2006. WDHR is a mandatory internet-based clinical registry including
data on all adults undergoing cardiac surgery in the western part of Den-
mark. Detailed data on patients, the surgical intervention, anesthesia, and
intensive care were collected prospectively. Data quality was ensured by
using automatic validation rules at data entry combined with systematic
validation procedures and random spot checks of data after entry. We iden-
tified 3625 procedures during the study period. Patients undergoing preop-
erative dialysis were excluded from the cohort (n ¼ 38), leaving 3587
(99.0%) patients for analysis.
Aminoglycoside Treatment
Since January 2003, all perioperative monitoring data and medications
were registered in an electronic patient management system. Data from the
WDHR and the electronic patient management system were merged, and
patients receiving perioperative aminoglycosides were identified. The ma-
jor indications for perioperative aminoglycoside treatment were reopera-
tion or endocarditis, covering 64.0% of administrations. Perioperative
aminoglycoside treatment was defined if administered between 48 hours
before and 24 hours after the start of the operation.ery c September 2011
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MAnesthesia Protocols and Perioperative Procedures
According to hospital guidelines, all preoperative cardiac medications
were continued until the morning of the operation except angiotensin-
converting enzyme inhibitors and platelet inhibitors, including aspirin,
which were continued in patients with acute coronary syndrome. Anesthe-
sia was primarily administered intravenously with propofol, sufentanil, and
pancuronium or rocuronium.
In the operating room patients were monitored routinely, including
5-lead electrocardiography, radial and pulmonary artery catheterization
with continuous cardiac output, pulse oximetry, capnography, and temper-
ature measurement. Most patients were also monitored with transesopha-
geal echocardiography.
Routine surgical and cardioprotective techniques were used in most pa-
tients: crystalloid cardioplegia together with closed CPB systems, consist-
ing of tubing with a surface-modifying additive coating; an arterial filter
with heparin coating; a hollow-fiber membrane oxygenator with a sur-
face-modified additive coating; and a venous cardiotomy reservoir. Patients
were maintained normothermic or slightly hypothermic. At the end of the
surgical procedure, reperfusion of the heart was performed individually ac-
cording to the patient’s general condition and crossclamp time. There was
no fixed postoperative treatment regimen concerning either pharmaceutical
or mechanical support.
Patient- and Procedure-Related Characteristics
Patients and procedures were characterized by using the EuroSCORE
variables (www.euroscore.org): age, sex, chronic pulmonary disease, ex-
tracardiac arteriopathy, neurologic dysfunction disease, previous cardiac
surgery, serum creatinine level, active endocarditis, critical peroperative
state, unstable angina, recent myocardial infarction, pulmonary hyperten-
sion, left ventricular dysfunction, emergency operation, and type of opera-
tion, together with diabetes, the Charlson Comorbidity Index, CPB time,
and use of peroperative and postoperative inotropic agents.
In addition, we computed the Charlson Comorbidity Index score based
on all discharge diagnoses recorded before the procedure.7 The Charlson
scores were based on the entire hospitalization history of each patient
back to 1977. We constructed the hospitalization history based on data
from the Danish National Hospital Registry, including data on all admis-
sions to Danish somatic hospitals since 1977, civil registry numbers of pa-
tients, dates of admission and discharge, surgical procedures performed,
and up to 20 diagnoses classified according to the International Classifica-
tion of Diseases system.*
Patient Outcome
Patient outcome included postoperative acute kidney injury and tempo-
rary or permanent in-hospital dialysis together with 30-day mortality post-
operatively. Definition of acute kidney injury was based on a consensus
report from the Acute Kidney Injury Network (AKIN),8 which is defined
by acute alterations in serum creatinine values or urine output. The pro-
posed definition takes into account the accumulating evidence that evenntil the end of 1993 and 10th revision thereafter for each hospital
1977 (since 1995, all hospital specialist outpatient visits).
The Journal of Thoracic and Casmall increments in serum creatinine values are associated with adverse
outcomes. Acute kidney injury is defined as an abrupt (within 48 hours) in-
crease in s-creatinine values of 26.2 mmol/L (0.3 mg/dL) or greater, a rela-
tive increase in serum creatinine values of 50% or greater, or a decrease in
urine output. However, because of the hemodilution normally found in con-
nection with CPB and cardiac surgery, we evaluated serum creatinine value
increases within 72 hours postoperatively.
Statistical Analyses
Comparison of the characteristics of the patients and procedure between
the aminoglycoside and control groups was made by using the c2 or
Fisher’s exact tests for categorical variables and the Student’s t test for con-
tinuous variables or the Mann-Whitney test if the variable did not have
a normal distribution. Univariate analyses were conducted to identify vari-
ables significantly associated with postoperative dialysis. These variables
were entered into multivariate logistic regression models by using the fol-
lowing outcomes: postoperative dialysis, increase in s-creatinine value, and
30-day mortality.
In addition to the analyses based on the entire study population, we also
did an analysis on a propensity score–matched subset of the population to
overcome bias caused by confounding. In this analysis we matched the pa-
tients receiving aminoglycosides to control subjects in a 1:1 ratio. We iden-
tified a set of aminoglycoside-treated patients and control subjects who had
a similar baseline chance of being treated with aminoglycosides. This was
followed by logistic regression analysis to compute odds ratios (ORs) of
postoperative dialysis. This 2-step procedure makes the model-based infer-
ences considerably less model dependent and generally more accurate.9 Co-
variates included in the propensity score included the additive EuroSCORE
(0-2, 3-5, and 6), the Charlson Comorbidity Index score (0, 1, and 2),
CPB time of greater than120 minutes, and perioperative inotropic treatment
and use of aprotinin. Then, using a macro based on a greedy algorithm
(http://www2.sas.com/proceedings/sugi26/p214-26.pdf), we matched each
aminoglycoside-treated patient to a unique control subject (patients who
did not aminoglycosides) on the propensity score alone. Thus we started
with a 5-digit match, and if this could not be done, we then continued to
a 4-, 3-, 2-, or 1-digit match. Unmatched aminoglycoside-treated patients
were excluded. We were able to match 78 aminoglycoside-treated patients
to 78 unique nonaminoglycoside-treated control subjects. We evaluated
the balance of the covariates using standardized differences and variance ra-
tios. After the matching, we did a logistic regression analysis and included
the same covariates as in the main analysis.
Analyses were performed with MedCalc software version 10.1.2 (Ma-
riakerke, Belgium) and SAS software version 9.2 (SAS Institute Inc,
Cary, NC).RESULTS
Demographics and perioperative risk factors according to
aminoglycoside treatment are shown in Table 1. Character-
istics are presented as independent variables combined into
computed score indices when relevant.
A total of 846 (23.7%) patients had acute kidney injury
defined as absolute increase in s-creatinine values of 26.2
mmol/L (0.3 mg/dL) or greater within 72 hours after car-
diac surgery, whereas kidney injury defined as a relative in-
crease in s-creatinine values of more than 50% of
preoperative s-creatinine was seen in 458 (12.8%) patients.
Patients with a greater than 50% s-creatinine value increase
had increased median lengths of hospital stay (7.82 vs 5.42
days; P< .0001, c2 test) and increased 30-day mortality
rates (10.9% vs 2.5%; P<.0001, t test).rdiovascular Surgery c Volume 142, Number 3 657
TABLE 1. Descriptive characteristics of selected data depending on
aminoglycoside treatment
Aminoglycoside
group
Nonaminoglycoside
group
P
value
No. of patients 89 3498
Age, y (mean  SD) 59.7  14.7 65.1  12.0 <.0001
Female sex (%) 19.1 28.4 .07
Overall EuroSCORE
(mean  SD)
9.98  4.52 5.78  3.46 <.0001
COPD (%)* 10.1 12.0 .705
Preoperative artery
disease (%)*
9.0 9.0 .854
Pre-CNS disease (%)* 24.4 9.1 <.0001
Previous cardiac
surgery (%)*
20.2 6.4 <.0001
S-creatinine>200
mmol1 (%)*
3.4 1.9 .538
Endocarditis (%)* 58.4 1.5 <.0001
Critical preoperative
state (%)*
33.7 5.7 <.0001
Unstable angina (%)* 6.7 11.3 .237
AMI<90 days (%)* 4.5 14.4 .013
Pulmonary
hypertension (%)*
14.6 6.4 .004
LV dysfunction (%)* 55.0 56.0 .237
Acute operation (%)* 42.7 6.7 <.0001
Other than CABG (%)* 91.0 51.2 <.0001
Aortic surgery (%)* 14.6 4.5 <.0001
Post-VSD surgery (%)* – 0.3 .553
Postoperative IABP (%) – 0.9 .735
BMI, kg/m2
(mean  SD)
29.1  5.05 26.48  4.29 .322
Diabetes type 1 or 2 (%) 19.1 14.0 .227
Charlson Index score
(median [range],
comorbidity)
1 (0–8) 1 (0–10) .908
Crossclamp time, min
(mean  SD)
90.9  61.1 62.0  31.8 <.0001
CPB>120 min (%) 45.2 25.7 .0007
CPB time, min
(mean  SD)
143.1  61.1 103.2  31.9 <.0001
Peroperative inotropic
treatment (%)
40.4 20.9 <.0001
Redo postoperative
bleeding (%)
20.2 7.4 <.0001
Perioperative
aprotinin (%)
59.6 16.2 <.0001
Preoperative ACE
inhibitors (%)
27.5 31.1 .679
Preoperative
steroids (%)
2.0 2.4 .79
Values are presented as numbers (percentages), means  standard deviations, or me-
dians (ranges). SD, Standard deviation; COPD, chronic obstructive pulmonary dis-
ease; CNS, central nervous system; AMI, acute myocardial infarction; LV, left
ventricular; CABG, coronary artery bypass grafting; VSD, ventricular septal defect;
IABP, intra-aortic balloon pump; BMI, body mass index; CPB, cardiopulmonary by-
pass; ACE, angiotensin-converting enzyme. *Variables are based on EuroSCORE
definitions.
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MThe incidence of patients requiring dialysis was 3.2%
(n ¼ 115), of whom 20 (17.4%) did not fulfill our criteria
for acute kidney injury. Seven patients had preoperative
s-creatinine values of greater than 250 mmol/L, and kidney
injury was observed after 5 to 11 days in 11 patients; thus 2
patients underwent dialysis because of circulatory instabil-
ity and severe overloading. Only 1 of these 20 patients
received aminoglycosides.
Patients with endocarditis had a substantially higher risk
of requiring postoperative dialysis than patients without en-
docarditis (17.3% vs 2.6%). However, the proportion was
equally high among patients with endocarditis receiving
aminoglycoside treatment (9/52 [17.3%]) and patients
with endocarditis without aminoglycoside treatment (9/52
[17.3%]). Among the patients treated with aminoglyco-
sides for indications other than endocarditis, the proportion
requiring postoperative dialysis was 9 (24.3%) of 37.
Perioperative use of aminoglycosides was strongly asso-
ciatedwith the risk of postoperative dialysis both in the over-
all analyses (adjusted OR, 4.41; 95% confidence interval
[CI], 1.83–10.59) and in the propensity score–matched sub-
analysis (adjustedOR, 5.00; 95%CI, 1.28–19.54).Other pa-
tient- and procedure-related characteristics associated with
a higher risk of requiring postoperative dialysis included
the following: age, CharlsonComorbidity Index score, a pre-
operative high s-creatinine value(>200 mmol/L), hemody-
namic critical preoperative state, perioperative use of
aprotinin, CPB for longer than120 minutes, perioperative
inotropic treatment, and reoperation (Table 2).
The possible nephrotoxic effect of aminoglycoside treat-
ment was also indicated by a statistically significantly
higher increase and higher absolute values of s-creatinine
postoperatively in the aminoglycoside group (Table 3).
However, the aminoglycoside treatment was not indepen-
dently associated with higher mortality (Table 4).
DISCUSSION
Our study showed that perioperative aminoglycoside
treatment was associated with a higher risk of postoperative
acute kidney injury and dialysis among adult patients un-
dergoing cardiac surgery.
The incidence of acute kidney injury after cardiac sur-
gery varies across studies, with a range of 1% to 30%, re-
flecting the use of various definitions of kidney injury
associated with cardiac surgery. Mitter and colleagues10 re-
ported acute kidney injury to occur in 5.1% of women and
3.6% of men in a prospective study of 9461 patients under-
going cardiac surgery using the RIFFLE classification sys-
tem. In the present study acute kidney injury was defined by
AKIN stage 1,8 although it was slightly modified because
peak creatinine values were measured up to 72 hours post-
operatively. The need for an extended time window was
supported by the fact that 68.9% had a lower s-creatinine
value on the first postoperative day than preoperatively;ery c September 2011
TABLE 2. Crude andmutual adjusted risk of postoperative dialysis associated with selected patient- and procedure-related characteristics among
all patients and in a subset of aminoglycoside-treated patients and propensity score–matched control subjects
All patients Propensity score–matched patients
Factor Crude OR (95% CI) Adjusted OR (95% CI) Adjusted OR (95% CI)
Perioperative aminoglycosides 8.89 (5.10–15.5) 4.41 (1.83–10.59) 5.00 (1.28–19.54)
Age score (EuroSCORE definition) 1.17 (1.04–1.31) 1.23 (1.08–1.42) 1.50 (1.01–2.23)
Comorbidity factor (Charlson score) 1.30 (1.17–1.44) 1.17 (1.02–1.34) 1.30 (0.97–1.75)
Previous operation 2.90 (1.74–4.83) 1.68 (0.87–3.26) 1.20 (0.26–5.49)
s-Creatinine>200 mmol/L 15.94 (9.17–27.68) 10.33 (4.76–22.44) –
Endocarditis 7.31 (4.23–12.62) 0.93 (0.37–2.33) 0.28 (0.06–1.34)
Critical preoperative state 9.32 (6.18–14.05) 2.17 (1.21–3.91) 1.43 (0.40–5.06)
Preoperative cardiac state (EuroSCORE) 1.34 (1.22–1.47) 1.11 (0.97–1.27) 0.72 (0.48–1.08)
Other than CABG 3.08 (1.99–4.77) 1.20 (0.66–2.20) 0.48 (0.07–3.44)
Aortic operation 3.45 (1.99–6.01) 1.55 (0.74–3.22) 1.53 (0.33–7.19)
Perioperative aprotinin 4.89 (3.35–7.13) 1.98 (1.20–3.26) 2.92 (0.72–11.89)
CPB time>120 min 4.57 (3.10–6.74) 1.95 (1.19–3.20) 3.61 (1.00–13.02)
Perioperative inotropic treatment 4.61 (3.56–5.97) 2.10 (1.49–2.95) 3.27 (1.35–7.93)
Redo operation (bleeding or ischemia) 3.92 (2.51–6.10) 2.80 (1.63–4.80) 5.18 (1.35–19.98)
Preoperative cardiac status is a combined score of unstable angina, acute myocardial infarction of less than 90 days, pulmonary hypertension, and acute surgical intervention (all
EuroSCORE definitions). OR, Odds ratio; CI, confidence interval; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass.
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had a lower s-creatinine value. Likewise, Haase and associ-
ates11 showed that AKIN classification might miss patients
who experience their peak serum creatinine values from day
3 onward.
The proportion of patients with acute kidney injury re-
quiring dialysis was 11.2%; this is somewhat higher than
reported in other comprehensive cohort studies.12 Our
data did not make it possible to identify the exact criteria
for initiating dialysis because decisions were based on clin-
ical judgments. During the last decade, the reported rates of
patients requiring dialysis after cardiac surgery have ranged
between 0.6% and 2.2%.13-15 The present study revealed
a higher rate of 3.2%. This higher incidence might be
a result of the large proportion of patients undergoing
complex procedures (51.4%), along with less restrictiveTABLE 3. Perioperative aminoglycoside treatment and incidence of
acute kidney injury and postoperative dialysis
Aminoglycoside
group
Control
group P value
Preoperative s-creatinine
(mmol/L)
89 (82–98) 87 (86–87) .173*
Maximal postoperative
s-creatinine (mmol/L)
127 (114–156) 99 (98–101) <.0001*
Maximal increase in
s-creatinine (mmol/L)
34.0 (22.8–40.2) 10.0 (9.0–10.0) <.0001*
Increase>26.2 mmol/L 52 (58.4%) 794 (22.8%) <.0001y
Increase>50% 31 (34.8%) 427 (12.2%) <.0001y
Postoperative dialysis 18 (20.2%) 97 (2.8%) <.0001y
The maximum values and increase in s-creatinine values are within the first 72 hours
postoperatively. Values are indicated as medians (95% confidence intervals). The
differences between the aminoglycoside group and the control group were all statis-
tically significant except the preoperative s-creatinine value. *Mann-Whitney
independent-samples test. yc2 test.
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Mcriteria for initiating dialysis. Furthermore, in relation to
development of acute kidney injury in relation to cardiac
surgery, it should be noted that 20 (17.4%) of the patients
undergoing dialysis did not fulfill the AKIN criteria for
acute kidney injury (>26.2 mmol/L s-creatinine).
However, in 11 patients the kidney injury manifested later
(5–11 days after the operation); this indicates that
s-creatinine value changes and dialysis after cardiac
surgery are difficult to diagnose according to AKIN
classification because a late s-creatinine value increase
was seen in 5.2% of all patients. Moreover, a minority of
patients (n ¼ 7) with preoperative increased s-creatinine
values of greater than 250 mmol/L underwent dialysis,
most likely as a prophylactic precaution.
The effectiveness and safety of aminoglycoside therapy
has been discussed in several meta-analyses.16,17 In recent
guidelines from the Society of Thoracic Surgeons (2007)
aminoglycosides are only considered reasonable
prophylactic antibiotics in addition to vancomycin in
patients allergic to penicillin.1
In a Danish cohort study of 1257 adult patients with bac-
teremia, it was concluded that aminoglycoside combination
treatment was not associated with an increased 30-day mor-
tality rate and only a modest risk of increased serum creat-
inine values.18 Similar findings were found in a cohort study
among Danish patients with infective endocarditis: patients
treated with gentamicin had decreased kidney function
compared with patients not treated with gentamicin. How-
ever, the decrease was not associated with postdischarge
mortality.19 Another Danish study examined a possible as-
sociation between nephrotoxicity and prophylactic use of
dicloxacillin and gentamicin among orthopedic patients.
The study found a statistically significant increase in
s-creatinine values (greater than the upper standard 95%rdiovascular Surgery c Volume 142, Number 3 659
TABLE 4. Crude and adjusted odds ratios of postoperative complications related to postoperative dialysis
Postoperative complication
Aminoglycosides
Crude OR (95% CI) Adjusted OR (95% CI)No (n ¼ 3498 [%]) Yes (n ¼ 89 [%])
Postoperative dialysis 97 (2.8) 18 (20.2) 8.89 (5.10–15.5) 4.41 (1.83–10.59)
Increase s-creatinine>26.2 mmol/L 794 (22.8) 52 (58.4) 3.82 (2.44–5.98) 2.98 (1.76–5.05)
Increase s-creatinine>50% 427 (12.3) 31 (34.8) 4.75 (3.10–7.30) 1.77 (1.01–3.09)
30-d Mortality 137 (3.9) 9 (10.1) 2.76 (1.35–5.61) 0.39 (0.14–1.14)
Adjusted odds ratios are adjusted for factors included in Table 2. OR, Odds ratio; CI, confidence interval.
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Mlimit) postoperatively among patients receiving prophylac-
tic use of dicloxacillin and gentamicin compared with those
seen in patients not receiving prophylactic antibiotics and
no significant effect on wound infections.20
The majority of the findings in the present study were
consistentwith those of previous studies, identifyinghemody-
namic instability reflected in reoperation caused by bleeding
and peroperative inotropic support and perioperative use of
aprotinin as independent risk factors for dialysis-dependent
acute renal injury.13-15,21-23 However, the association
between perioperative aminoglycoside treatment and the
development of acute kidney injury requiring postoperative
dialysis, to our knowledge, provides new information.
Patients receiving aminoglycosides did have a marginally
higher, although not significant, preoperative s-creatinine
value but showed a statistically significantly higher increase
after surgical intervention (34 vs 10 mmol/L, Table 3) and
a more than 2-fold increase in patients fulfilling the criteria
for acute kidney injury, indicating an independent negative ef-
fect on kidney function. In accordance with the studies of
Freundlich and coworkers18 and Buchholtz and colleagues,19
aminoglycoside treatment was not independently associated
with higher mortality.
During CPB and re-establishment of pulsatile flow, an is-
chemia–reperfusion injury occurs to the renal vascular bed;
this might be one of the main reasons for acute kidney injury
after cardiac surgery. It has been demonstrated in animal
studies on rats that aminoglycosides exacerbate postische-
mic acute renal injury by influencing the reperfusion process
adversely.24 A retrospective study has demonstrated that
a combination of polygeline 3.5% primewith a high calcium
concentration and aminoglycosides might result in renal im-
pairment in patients undergoing cardiac surgery.5 In accor-
dance with the present findings, another study concluded
that simultaneous administration of high-dose aprotinin
and prophylactic use of aminoglycosides increase serum
concentrations of cystatin C and creatinine in the first post-
operative week in patients undergoing cardiac surgery.25Strengths and Limitations of the Study
The main strength of our study is the prospective
population-based design with complete follow-up for
a broad range of clinical outcomes and consequently the
low risk of selection and information bias. Furthermore, de-660 The Journal of Thoracic and Cardiovascular Surgtailed and complete data on patient- and procedure-related
characteristics were available. However, this is a historical
observation study, and conclusions are necessarily limited
in their application. Although we adjusted for a wide range
of possible confounding factors in the data analyses supple-
mented with a propensity score–matched subanalysis, it is
evident that patients receiving aminoglycosides in the peri-
operative period in many aspects have an adverse prognos-
tic profile compared with patients not treated with
aminoglycosides. Thus we cannot entirely exclude the pos-
sibility that residual or unaccounted confounding still might
influence the findings of the present study.
Our results show that the consensus criteria for acute
kidney injury are difficult to apply in patients undergoing
cardiac surgery, even after extending the postoperative
time window from 48 to 72 hours. Another 5.2% of the pa-
tients had a late increase in s-creatinine values, and in this
group we found 9.6% of patients undergoing dialysis,
thus indicating that kidney injury might be diagnosed differ-
ently in cardiac surgery patients.
CONCLUSIONS
In the present cohort study of 3587 adults undergoing car-
diac surgery, perioperative aminoglycoside treatment was
associated with a higher risk of acute kidney injury and
postoperative dialysis, even after taking factors of hemody-
namic instability into account. However, use of aminogly-
cosides appeared not to be independently associated with
a 30-day mortality rate.
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